Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza

Seyed M. Moghadas, Christopher S. Bowman, Gergely Röst et al. · 2008

Read Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza by Seyed M. Moghadas, Christopher S. Bowman, Gergely Röst et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001839.txt.

Introduction

Seyed M. Moghadas, Christopher S. Bowman, and Gergely Röst modeled antiviral resistance in a flu pandemic in a 2008 PLOS ONE research article. Resistance to the main flu drugs raised concerns about careful use of antiviral drugs in the next influenza pandemic. Resistant strains may start off weaker, but later mutations can restore much of that lost fitness.

The team modeled how resistance spreads during a pandemic under different drug use plans. The full text gives the scenarios and the timelines. Stockpiled antivirals are a central flu plan. If heavy use breeds resistance fast, planners must weigh treatment against prophylaxis with that risk included.

Catalog record

CREATORSeyed M. Moghadas, Christopher S. Bowman, Gergely Röst et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001839

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza Authors: Seyed M. Moghadas, Christopher S. Bowman, Gergely Röst, Jianhong Wu Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001839 ABSTRACT The emergence of neuraminidase inhibitor resistance has raised concerns about the prudent use of antiviral drugs in response to the next influenza pandemic. While resistant strains may initially emerge with compromised viral fitness, mutations that largely compensate for this impaired fitness can arise. Understanding the extent to which these mutations affect the spread of disease in the population can have important implications for developing pandemic plans. By employing a deterministic mathematical model, we investigate possible scenarios for the emergence of population-wide resistance in the presence of antiviral drugs. The results show that if the treatment level (the fraction of clinical infections which receives treatment) is maintained constant during the course of the outbreak, there is an optimal level that minimizes the final size of the pandemic. However, aggressive treatment above the optimal level can substantially promote the spread of highly transmissible resistant mutants and increase the total number of infections. We demonstrate that resistant outbreaks can occur more readily when the spread of disease is further delayed by applying other curtailing measures, even if treatment levels are kept modest. However, by changing treatment levels over the course of the pandemic, it is possible to reduce the final size of the pandemic below the minimum achieved at the optimal constant level. This reduction can occur with low treatment levels during the early stages of the pandemic, followed by a sharp increase in drug-use before the virus becomes widely spread. Our findings suggest that an adaptive antiviral strategy with conservative initial treatment levels, followed by a timely increase in the scale of drug-use, can minimize the final size of a pandemic while preventing large outbreaks of resistant infections. INTRODUCTION The use of antiviral drugs to mitigate the impact of a nascent influenza pandemic has been evaluated in several recent modelling studies [1] – [7] , with significant public health implications for identifying effective preparedness strategies. These studies suggest that early diagnosis and prompt onset of treatment of clinical cases is crucial for possible containment of a pandemic. A key assumption is that the virus remains less transmissible than pandemic viruses of the last century, so that the reproduction number of disease transmission stays below 1.8 [1] , [6] , [7] . However, the effectiveness of antiviral drugs may be diminished by several factors, including a delay in start of treatment, and more importantly, the emergence and transmission of drug-resistant viral mutants in the population [8] – [12] . While antiviral therapy appears to be central in any containment strategy, it will impact the emergence of drug-resistance in a complex manner. On one hand, early application of antiviral drugs will largely inhibit generation of resistant viruses by suppressing viral replication. On the other hand, it results in a longer time for selection in favour of pre-existing resistant mutants to restore their impaired replication fitness through compensatory mutations [13] , [14] . With sufficiently increased fitness, resistant viruses may gain a competitive advantage in the spread of infection and establish a self-sustaining epidemic of viral resistance [8] , [9] , [14] . Strategic use of antiviral drugs is therefore crucial for not only mitigating the impact of the wild-type strain, but also preventing the occurrence of pandemic waves of drug-resistant infections. The dynamics of competition between the wild-type and resistant strains is in general complex. If treatment is poorly administered, then the wild-type strain spreads rapidly and depletes the pool of susceptibles in the population, which would afford little chance for resistant strains to evolve or cause an outbreak of drug-resistance [8] , [9] . It has been suggested that intensive antiviral treatment may eliminate the wild-type infection (when transmission of the virus is largely interrupted) without promoting the spread of resistant strains if transmissibility of resistant strains is sufficiently low [9] . Regardless of the feasibility of such antiviral strategy, high treatment levels can exert strong selective pressures that confer resistance that frequently evolves far more rapidly than the natural rate. The evolution of such mutants is influenced by several factors, including the duration of treatment, the delay in onset of therapy, and the rate at which de novo resistant mutations occur [8] . Combined with compensatory mutations that raise fitness of resistant viruses [13] , [14] , intensive treatment may indeed result in a devastating pandemic of resistant viral mutants. Understanding the dynamics of the emergence of drug-resistance is therefore crucial for implementation of effective mitigation strategies. In this paper, we extend previous work [8] , [15] to illustrate the possible scenarios of disease outbreak in the population, including single-strain infections and co-existence of wild-type and resistant infections. By incorporating compensatory mutations into a mathematical model, we discuss the role of the transmission fitness of resistant mutants in determining the outcomes of antiviral strategies with constant and varying treatment levels. In the following, we describe the model based on the existing frameworks [8] , [15] , and provide details of the equations and analysis in “ Text S1 ”. We derive the control reproduction number of the wild-type strain and use it for delineating the results and their epidemiological consequences for the strategic use of antiviral drugs in response to a future pandemic. METHODS To develop a population dynamical model, we followed previous work [8] , [15] and divided the population into several compartments comprising susceptible, exposed, asymptomatic, and symptomatic infected individuals. In our model, exposed individuals undergo a latent period, during which viral titers increase to detectable and transmissible levels [16] . An exposed individual may become infectious after the latent period and shed virus without showing clinical symptoms; this is referred to as asymptomatic infection. Considering the kinetics of influenza infection in humans [16] , we divided the clinical course of infection into three stages: (i) pre-symptomatic infection, (ii) primary stage of symptomatic infection (referred to as the window of opportunity for start of treatment); and (iii) secondary stage of symptomatic infection ( Figure 1 ). The relative transmissibility of the virus at each stage is estimated by superposing a step-function on the log-normal curve fitted to household longitudinal data on influenza viral shedding [1] , [17] . Antiviral treatment, as a single containment strategy, may be initiated upon diagnosis of a clinical case within the window of opportunity; however, those who have not started treatment in this window will receive no antiviral therapy during the secondary stage of symptomatic infection. The probability of an individual receiving treatment decreases with the time elapsed since the onset of symptoms, which is reflected in the functional form of the treatment rate with delay in seeking healthcare [8] , [15] . We assumed that treatment reduces the infectiousness level of the wild-type disease by 60% (reflected as a reduced transmission rate in the model since initiation of treatment), but has no effect on individuals infected with resistant viruses. The clinical course of disease is divided into three stages: pre-symptomatic; primary; and secondary stages of symptomatic infections. Drug-resistance with low transmission fitness can emerge during treatment of individuals infected with the wild-type virus. It is assumed that compensatory

Read the complete text